DEA Approves New Exempt Chemical Mixtures
Published Date: 5/20/2026
Notice
Summary
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Certain lab mixtures exempted from parts of CSA
DEA approved specific chemical preparations listed in Chart I (applications received July 1, 2025 through March 31, 2026) as exempt from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the Controlled Substances Act and from 21 CFR 1301.74, effective as of the dates in the approval letters. The exemptions apply only to the exact preparations and forms described in the applications.
Some applications denied — products remain regulated
DEA determined that the chemical preparations listed in Chart II (applications received July 1, 2025 through March 31, 2026) are not exempt, so those specific products remain subject to all parts of the Controlled Substances Act and related regulations as of the dates in the determination letters. Companies listed in Chart II must comply with CSA and CFR requirements for those products.
Bulk-exempt products limited to in-house use
For exempted bulk products listed in this order, DEA determined they may only be used in-house by the manufacturer and may not be distributed for any purpose or transported to other facilities. This restriction is intended to limit diversion from larger bulk quantities.
Exemptions limited to exact formulation — changes need refile
The exemptions apply only to the precise composition, form, and trade name described in each application; any change in quantitative or qualitative composition or in the trade name after the application date requires a new application under 21 CFR 1308.24(h).
Other CSA requirements still apply (importer registration)
DEA states that the exemptions are limited to the specific CSA/CFR sections identified in 21 CFR 1308.24(a); all other CSA and CFR requirements remain in force, including registration as an importer as required by 21 U.S.C. 957. Affected entities must still meet those other obligations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-10089, Importer of Controlled Substances Application: Amneal Pharmaceuticals, LLC
Amneal Pharmaceuticals wants to become an official importer of a strong painkiller called Remifentanil. This means they’ll be allowed to bring this controlled drug into the U.S. People who make or use these drugs can share their thoughts or ask for a hearing by June 22, 2026. No direct money changes yet, but this move could affect drug availability and business in the future.
Next: 2026-10091, Commission Information Collection Activities (FERC-919); Comment Request; Extension
FERC is extending its current info collection rules for another three years without any changes. This affects public utilities that sell electricity at market-based rates, making sure their prices stay fair. If you want to share your thoughts, you’ve got until July 20, 2026, to comment—no extra costs or new paperwork coming your way!